The pace of drug development can be maddeningly slow. The fact that we had our final, blockbuster results in May of 2020, and that we might not be able to start dosing for the Phase IIB until Q2 2022 -- two years later is quite honestly disgraceful and a complete disservice to the boys who suffer from this disease, most of whom only have twenty something years to live.
Ann: ATL1102 DMD Paediatric Investigation Plan submitted to EMA, page-43
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.8¢ |
Change
-0.003(3.70%) |
Mkt cap ! $82.67M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.1¢ | 7.8¢ | $215.5K | 2.715M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 137820 | 7.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 319232 | 3 |
View Market Depth
| Last trade - 15.59pm 19/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |